{"id":2387,"date":"2021-07-20T11:24:00","date_gmt":"2021-07-20T09:24:00","guid":{"rendered":"https:\/\/www.institut-myologie.org\/imotion\/?p=2387"},"modified":"2021-07-23T11:27:11","modified_gmt":"2021-07-23T09:27:11","slug":"dmd-start-at-i-motion-of-trials-with-pamrevlumab-in-ambulatory-and-non-ambulatory-patients","status":"publish","type":"post","link":"https:\/\/www.institut-myologie.org\/imotion\/2021\/07\/20\/dmd-start-at-i-motion-of-trials-with-pamrevlumab-in-ambulatory-and-non-ambulatory-patients\/?lang=en","title":{"rendered":"DMD: start at I-Motion of trials with pamrevlumab in ambulatory and non-ambulatory patients"},"content":{"rendered":"\n

I-Motion is recruiting patients with Duchenne muscular dystrophy to participate in two pharmacological trials designed to test an antifibrotic monoclonal antibody, pamrevlumab (or FG-3019), developed by FibroGen.<\/p>\n\n\n\n

The objective of these phase III trials is to assess the tolerance, safety and efficacy on the upper limbs, respiratory and cardiac functions of pamrevlumab administered by intravenous infusion in combination with oral corticosteroids in boys. with DMD, over 12 years old, ambulant (trial FGCL-3019-094) or non-ambulant (trial FGCL-3019-093).<\/p>\n\n\n\n

Dr Silvana De Lucia is the principal investigator in these two trials at the I-Motion site.<\/p>\n\n\n\n

Further details on trials FGCL-3019-094<\/a> and FGCL-3019-093<\/a><\/p><\/blockquote>\n","protected":false},"excerpt":{"rendered":"

I-Motion is recruiting patients with Duchenne muscular dystrophy to participate in two pharmacological trials designed to test an antifibrotic monoclonal antibody, pamrevlumab (or FG-3019), developed by FibroGen. The objective of these phase III trials is to assess the tolerance, safety and efficacy on the upper limbs, respiratory and cardiac functions of pamrevlumab administered by intravenous … Continued<\/a><\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[3],"tags":[],"class_list":["post-2387","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"acf":[],"yoast_head":"\nDMD: start at I-Motion of trials with pamrevlumab in ambulatory and non-ambulatory patients - I-Motion<\/title>\n<meta name=\"description\" content=\"Recruitment of patients with DMD to participate in trials designed to test an antifibrotic monoclonal antibody, pamrevlumab (or FG-3019).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.institut-myologie.org\/imotion\/2021\/07\/20\/dmd-start-at-i-motion-of-trials-with-pamrevlumab-in-ambulatory-and-non-ambulatory-patients\/?lang=en\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"DMD: start at I-Motion of trials with pamrevlumab in ambulatory and non-ambulatory patients - I-Motion\" \/>\n<meta property=\"og:description\" content=\"Recruitment of patients with DMD to participate in trials designed to test an antifibrotic monoclonal antibody, pamrevlumab (or FG-3019).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.institut-myologie.org\/imotion\/2021\/07\/20\/dmd-start-at-i-motion-of-trials-with-pamrevlumab-in-ambulatory-and-non-ambulatory-patients\/?lang=en\" \/>\n<meta property=\"og:site_name\" content=\"I-Motion\" \/>\n<meta property=\"article:published_time\" content=\"2021-07-20T09:24:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-07-23T09:27:11+00:00\" \/>\n<meta name=\"author\" content=\"Anne Berthomier\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"Anne Berthomier\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.institut-myologie.org\/imotion\/2021\/07\/20\/dmd-start-at-i-motion-of-trials-with-pamrevlumab-in-ambulatory-and-non-ambulatory-patients\/?lang=en#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.institut-myologie.org\/imotion\/2021\/07\/20\/dmd-start-at-i-motion-of-trials-with-pamrevlumab-in-ambulatory-and-non-ambulatory-patients\/?lang=en\"},\"author\":{\"name\":\"Anne Berthomier\",\"@id\":\"https:\/\/www.institut-myologie.org\/imotion\/#\/schema\/person\/ecf0b87715a026a200491fe2d7649def\"},\"headline\":\"DMD: start at I-Motion of trials with pamrevlumab in ambulatory and non-ambulatory patients\",\"datePublished\":\"2021-07-20T09:24:00+00:00\",\"dateModified\":\"2021-07-23T09:27:11+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.institut-myologie.org\/imotion\/2021\/07\/20\/dmd-start-at-i-motion-of-trials-with-pamrevlumab-in-ambulatory-and-non-ambulatory-patients\/?lang=en\"},\"wordCount\":117,\"publisher\":{\"@id\":\"https:\/\/www.institut-myologie.org\/imotion\/#organization\"},\"articleSection\":[\"Uncategorized\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.institut-myologie.org\/imotion\/2021\/07\/20\/dmd-start-at-i-motion-of-trials-with-pamrevlumab-in-ambulatory-and-non-ambulatory-patients\/?lang=en\",\"url\":\"https:\/\/www.institut-myologie.org\/imotion\/2021\/07\/20\/dmd-start-at-i-motion-of-trials-with-pamrevlumab-in-ambulatory-and-non-ambulatory-patients\/?lang=en\",\"name\":\"DMD: start at I-Motion of trials with pamrevlumab in ambulatory and non-ambulatory patients - I-Motion\",\"isPartOf\":{\"@id\":\"https:\/\/www.institut-myologie.org\/imotion\/#website\"},\"datePublished\":\"2021-07-20T09:24:00+00:00\",\"dateModified\":\"2021-07-23T09:27:11+00:00\",\"description\":\"Recruitment of patients with DMD to participate in trials designed to test an antifibrotic monoclonal antibody, pamrevlumab (or FG-3019).\",\"breadcrumb\":{\"@id\":\"https:\/\/www.institut-myologie.org\/imotion\/2021\/07\/20\/dmd-start-at-i-motion-of-trials-with-pamrevlumab-in-ambulatory-and-non-ambulatory-patients\/?lang=en#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.institut-myologie.org\/imotion\/2021\/07\/20\/dmd-start-at-i-motion-of-trials-with-pamrevlumab-in-ambulatory-and-non-ambulatory-patients\/?lang=en\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.institut-myologie.org\/imotion\/2021\/07\/20\/dmd-start-at-i-motion-of-trials-with-pamrevlumab-in-ambulatory-and-non-ambulatory-patients\/?lang=en#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.institut-myologie.org\/imotion\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"DMD: start at I-Motion of trials with pamrevlumab in ambulatory and non-ambulatory patients\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.institut-myologie.org\/imotion\/#website\",\"url\":\"https:\/\/www.institut-myologie.org\/imotion\/\",\"name\":\"I-Motion\",\"description\":\"Plateforme d'essais cliniques p\u00e9diatriques pour les maladies neuromusculaires\",\"publisher\":{\"@id\":\"https:\/\/www.institut-myologie.org\/imotion\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.institut-myologie.org\/imotion\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.institut-myologie.org\/imotion\/#organization\",\"name\":\"Institut I-Motion\",\"url\":\"https:\/\/www.institut-myologie.org\/imotion\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.institut-myologie.org\/imotion\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.institut-myologie.org\/imotion\/wp-content\/uploads\/2016\/08\/logoImotion.png\",\"contentUrl\":\"https:\/\/www.institut-myologie.org\/imotion\/wp-content\/uploads\/2016\/08\/logoImotion.png\",\"width\":150,\"height\":51,\"caption\":\"Institut I-Motion\"},\"image\":{\"@id\":\"https:\/\/www.institut-myologie.org\/imotion\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.institut-myologie.org\/imotion\/#\/schema\/person\/ecf0b87715a026a200491fe2d7649def\",\"name\":\"Anne Berthomier\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.institut-myologie.org\/imotion\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/86282695a210f7767b59efc8eb542fb81270ad9c1a9d8bb3bccd9ab2f96782e6?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/86282695a210f7767b59efc8eb542fb81270ad9c1a9d8bb3bccd9ab2f96782e6?s=96&d=mm&r=g\",\"caption\":\"Anne Berthomier\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"DMD: start at I-Motion of trials with pamrevlumab in ambulatory and non-ambulatory patients - I-Motion","description":"Recruitment of patients with DMD to participate in trials designed to test an antifibrotic monoclonal antibody, pamrevlumab (or FG-3019).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.institut-myologie.org\/imotion\/2021\/07\/20\/dmd-start-at-i-motion-of-trials-with-pamrevlumab-in-ambulatory-and-non-ambulatory-patients\/?lang=en","og_locale":"fr_FR","og_type":"article","og_title":"DMD: start at I-Motion of trials with pamrevlumab in ambulatory and non-ambulatory patients - I-Motion","og_description":"Recruitment of patients with DMD to participate in trials designed to test an antifibrotic monoclonal antibody, pamrevlumab (or FG-3019).","og_url":"https:\/\/www.institut-myologie.org\/imotion\/2021\/07\/20\/dmd-start-at-i-motion-of-trials-with-pamrevlumab-in-ambulatory-and-non-ambulatory-patients\/?lang=en","og_site_name":"I-Motion","article_published_time":"2021-07-20T09:24:00+00:00","article_modified_time":"2021-07-23T09:27:11+00:00","author":"Anne Berthomier","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"Anne Berthomier","Dur\u00e9e de lecture estim\u00e9e":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.institut-myologie.org\/imotion\/2021\/07\/20\/dmd-start-at-i-motion-of-trials-with-pamrevlumab-in-ambulatory-and-non-ambulatory-patients\/?lang=en#article","isPartOf":{"@id":"https:\/\/www.institut-myologie.org\/imotion\/2021\/07\/20\/dmd-start-at-i-motion-of-trials-with-pamrevlumab-in-ambulatory-and-non-ambulatory-patients\/?lang=en"},"author":{"name":"Anne Berthomier","@id":"https:\/\/www.institut-myologie.org\/imotion\/#\/schema\/person\/ecf0b87715a026a200491fe2d7649def"},"headline":"DMD: start at I-Motion of trials with pamrevlumab in ambulatory and non-ambulatory patients","datePublished":"2021-07-20T09:24:00+00:00","dateModified":"2021-07-23T09:27:11+00:00","mainEntityOfPage":{"@id":"https:\/\/www.institut-myologie.org\/imotion\/2021\/07\/20\/dmd-start-at-i-motion-of-trials-with-pamrevlumab-in-ambulatory-and-non-ambulatory-patients\/?lang=en"},"wordCount":117,"publisher":{"@id":"https:\/\/www.institut-myologie.org\/imotion\/#organization"},"articleSection":["Uncategorized"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/www.institut-myologie.org\/imotion\/2021\/07\/20\/dmd-start-at-i-motion-of-trials-with-pamrevlumab-in-ambulatory-and-non-ambulatory-patients\/?lang=en","url":"https:\/\/www.institut-myologie.org\/imotion\/2021\/07\/20\/dmd-start-at-i-motion-of-trials-with-pamrevlumab-in-ambulatory-and-non-ambulatory-patients\/?lang=en","name":"DMD: start at I-Motion of trials with pamrevlumab in ambulatory and non-ambulatory patients - I-Motion","isPartOf":{"@id":"https:\/\/www.institut-myologie.org\/imotion\/#website"},"datePublished":"2021-07-20T09:24:00+00:00","dateModified":"2021-07-23T09:27:11+00:00","description":"Recruitment of patients with DMD to participate in trials designed to test an antifibrotic monoclonal antibody, pamrevlumab (or FG-3019).","breadcrumb":{"@id":"https:\/\/www.institut-myologie.org\/imotion\/2021\/07\/20\/dmd-start-at-i-motion-of-trials-with-pamrevlumab-in-ambulatory-and-non-ambulatory-patients\/?lang=en#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.institut-myologie.org\/imotion\/2021\/07\/20\/dmd-start-at-i-motion-of-trials-with-pamrevlumab-in-ambulatory-and-non-ambulatory-patients\/?lang=en"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.institut-myologie.org\/imotion\/2021\/07\/20\/dmd-start-at-i-motion-of-trials-with-pamrevlumab-in-ambulatory-and-non-ambulatory-patients\/?lang=en#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.institut-myologie.org\/imotion\/"},{"@type":"ListItem","position":2,"name":"DMD: start at I-Motion of trials with pamrevlumab in ambulatory and non-ambulatory patients"}]},{"@type":"WebSite","@id":"https:\/\/www.institut-myologie.org\/imotion\/#website","url":"https:\/\/www.institut-myologie.org\/imotion\/","name":"I-Motion","description":"Plateforme d'essais cliniques p\u00e9diatriques pour les maladies neuromusculaires","publisher":{"@id":"https:\/\/www.institut-myologie.org\/imotion\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.institut-myologie.org\/imotion\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.institut-myologie.org\/imotion\/#organization","name":"Institut I-Motion","url":"https:\/\/www.institut-myologie.org\/imotion\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.institut-myologie.org\/imotion\/#\/schema\/logo\/image\/","url":"https:\/\/www.institut-myologie.org\/imotion\/wp-content\/uploads\/2016\/08\/logoImotion.png","contentUrl":"https:\/\/www.institut-myologie.org\/imotion\/wp-content\/uploads\/2016\/08\/logoImotion.png","width":150,"height":51,"caption":"Institut I-Motion"},"image":{"@id":"https:\/\/www.institut-myologie.org\/imotion\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/www.institut-myologie.org\/imotion\/#\/schema\/person\/ecf0b87715a026a200491fe2d7649def","name":"Anne Berthomier","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.institut-myologie.org\/imotion\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/86282695a210f7767b59efc8eb542fb81270ad9c1a9d8bb3bccd9ab2f96782e6?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/86282695a210f7767b59efc8eb542fb81270ad9c1a9d8bb3bccd9ab2f96782e6?s=96&d=mm&r=g","caption":"Anne Berthomier"}}]}},"_links":{"self":[{"href":"https:\/\/www.institut-myologie.org\/imotion\/wp-json\/wp\/v2\/posts\/2387","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.institut-myologie.org\/imotion\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.institut-myologie.org\/imotion\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.institut-myologie.org\/imotion\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.institut-myologie.org\/imotion\/wp-json\/wp\/v2\/comments?post=2387"}],"version-history":[{"count":3,"href":"https:\/\/www.institut-myologie.org\/imotion\/wp-json\/wp\/v2\/posts\/2387\/revisions"}],"predecessor-version":[{"id":2391,"href":"https:\/\/www.institut-myologie.org\/imotion\/wp-json\/wp\/v2\/posts\/2387\/revisions\/2391"}],"wp:attachment":[{"href":"https:\/\/www.institut-myologie.org\/imotion\/wp-json\/wp\/v2\/media?parent=2387"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.institut-myologie.org\/imotion\/wp-json\/wp\/v2\/categories?post=2387"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.institut-myologie.org\/imotion\/wp-json\/wp\/v2\/tags?post=2387"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}